Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04980872 · ClinicalTrials.gov registry record · Phase 2
A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)
A Phase 2 study of PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS), sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 11
- Study locations
NCT04980872 is a Phase 2 study of PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS) that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 60 participants. The trial reports 11 study locations across 11 states.
The verdict
NCT04980872, a Phase 2 study of PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS), is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a study of the safety and tolerability of oral miransertib (MK-7075) administered to participants at least 2 years of age with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-related overgrowth spectrum (PROS) or Proteus Syndrome (PS). This is an extension of other miransertib studies (MK-7075-002 \[NCT03094832\] or ArQule CU/EAP \[NCT03317366\]), and may also enroll participants who are approved for MK-7075-002 but have not yet started miransertib therapy.
Conditions Studied
Interventions
- DRUG Miransertib
Study Locations (11)
Georgia
- Children's Healthcare of Atlanta - Egleston Hospital ( Site 0107) - Atlanta
Massachusetts
- Boston Children's Hospital ( Site 0089) - Boston
Ohio
- Cincinnati Children's Hospital Medical Center-Hematology ( Site 0102) - Cincinnati
Texas
- Texas Children's Hospital ( Site 0104) - Houston
Washington
- Seattle Children's Hospital ( Site 0103) - Seattle
New South Wales
- John Hunter Hospital ( Site 0203) - Newcastle
Queensland
- Bundaberg Base Hospital ( Site 0202) - Bundaberg
Goiás
- Hospital Araújo Jorge ( Site 0801) - Goiânia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-11-02 |
| Est. Completion | 2030-02-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04980872
The ClinicalTrials.gov registry entry for NCT04980872 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS) appearing as the primary indexed condition, and to 1 intervention - of which Miransertib is the first listed.
NCT04980872 reports 11 study locations spanning 11 distinct geographic areas - top geographies include Georgia, Massachusetts, Ohio.
Frequently Asked Questions
What is clinical trial NCT04980872 about?
NCT04980872 is a clinical study titled "A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)". This is a study of the safety and tolerability of oral miransertib (MK-7075) administered to participants at least 2 years of age with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-related overgrowth spectrum (PROS) or Proteus Syndrome (PS). This is an extension of ...
What is the current status of trial NCT04980872?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2021-11-02. Estimated completion is 2030-02-07.
What conditions does trial NCT04980872 study?
This clinical trial studies the following conditions: PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS).
What interventions are being tested in trial NCT04980872?
The interventions under investigation include: Miransertib (DRUG).
Who is sponsoring clinical trial NCT04980872?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04980872 being conducted?
This trial has 11 study locations across Georgia, Massachusetts, Ohio, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.